These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 35111663)

  • 41. CRISPR/Cas9 in Stem Cell Research: Current Application and Future Perspective.
    Patmanathan SN; Gnanasegaran N; Lim MN; Husaini R; Fakiruddin KS; Zakaria Z
    Curr Stem Cell Res Ther; 2018; 13(8):632-644. PubMed ID: 29895256
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
    Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
    J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope.
    Karn V; Sandhya S; Hsu W; Parashar D; Singh HN; Jha NK; Gupta S; Dubey NK; Kumar S
    Cancer Cell Int; 2022 Jul; 22(1):234. PubMed ID: 35879772
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications.
    Cheng H; Zhang F; Ding Y
    Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683943
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CRISPR/Cas9 Immune System as a Tool for Genome Engineering.
    Hryhorowicz M; Lipiński D; Zeyland J; Słomski R
    Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):233-240. PubMed ID: 27699445
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The applications of CRISPR screen in functional genomics.
    Qi X; Zhang J; Zhao Y; Chen T; Xiang Y; Hui J; Cai D; Liu Y; Xia L; Yu T; Li G
    Brief Funct Genomics; 2017 Jan; 16(1):34-37. PubMed ID: 27329784
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Application of CRISPR screen in mechanistic studies of tumor development, tumor drug resistance, and tumor immunotherapy.
    Li M; Sun J; Shi G
    Front Cell Dev Biol; 2023; 11():1220376. PubMed ID: 37427373
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent Advances in Genome Editing Using CRISPR/Cas9.
    Ding Y; Li H; Chen LL; Xie K
    Front Plant Sci; 2016; 7():703. PubMed ID: 27252719
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic status and the prospect of CRISPR/Cas9 gene editing in multiple myeloma.
    Hong L; Zhang C; Jiang Y; Liu H; Huang H; Guo D
    Future Oncol; 2020 Jun; 16(16):1125-1136. PubMed ID: 32338048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells.
    Mohammadian Gol T; Kim M; Sinn R; Ureña-Bailén G; Stegmeyer S; Gratz PG; Zahedipour F; Roig-Merino A; Antony JS; Mezger M
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003255
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy.
    Ito Y; Inoue S; Kagoya Y
    Inflamm Regen; 2024 Mar; 44(1):13. PubMed ID: 38468282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genome modification by CRISPR/Cas9.
    Ma Y; Zhang L; Huang X
    FEBS J; 2014 Dec; 281(23):5186-93. PubMed ID: 25315507
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges.
    Yi L; Li J
    Biochim Biophys Acta; 2016 Dec; 1866(2):197-207. PubMed ID: 27641687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CRISPR Cas System: An efficient tool for cancer modelling.
    Akhtar M; Jamal T; Khan M; Khan SR; Haider S; Jalil F
    J Pak Med Assoc; 2021 Feb; 71(2(B)):718-724. PubMed ID: 33941966
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles.
    Jo DH; Kaczmarek S; Shin O; Wang L; Cowan J; McComb S; Lee SH
    Mol Ther Methods Clin Dev; 2023 Jun; 29():173-184. PubMed ID: 37063482
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The role of CRISPR screening in leukemia research].
    Oshima K
    Rinsho Ketsueki; 2022; 63(11):1580-1585. PubMed ID: 36476800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CRISPR/Cas9 Genome Editing Technology: A Valuable Tool for Understanding Plant Cell Wall Biosynthesis and Function.
    Zhang Y; Showalter AM
    Front Plant Sci; 2020; 11():589517. PubMed ID: 33329650
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
    Liu X; Zhao Y
    Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CRISPR-Cas9 technology: applications and human disease modelling.
    Torres-Ruiz R; Rodriguez-Perales S
    Brief Funct Genomics; 2017 Jan; 16(1):4-12. PubMed ID: 27345434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.